絞り込み

16645

広告

新型ウイルス肺炎 北朝鮮国営航空 外国人観光客は乗せない対応

中国で新型のコロナウイルスによるものとみられる肺炎への感染が広がっている問題を受けた北朝鮮の動きです。北朝鮮国営のコリョ(高麗)航空はNHKの取材に対し、北京か...

  1. 新型ウイルス肺炎 マカオでも感染者を初確...
  2. 調達情報 中小企業のための女性活躍推進事...
  3. 調達情報 民間人材サービスの活用検討事業...
  4. 書店水槽に「ぴろぴろの何か」 絶滅危惧ド...

ニュース一覧

Review: Treatment of Helicobacter pylori Infection 2019.

著者 O'Connor A , Liou JM , Gisbert JP , O'Morain C
Helicobacter.2019 Sep ; 24 Suppl 1():e12640.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (57view , 0users)

Full Text Sources

This review summarizes important studies regarding Helicobacter pylori therapy published from May 2018 to May 2019. The main themes that emerge involve studies assessing the efficacy of bismuth-based regimens. While in recent years the efficacy of bismuth-based quadruple therapy as a second-line therapy has been clearly established, there is now substantial evidence that it is the best performing first-line therapy. Antibiotic resistance was again intensely studied this year, and a clear and dramatic increase in resistance is noted for clarithromycin and levofloxacin; most notably, it may not be possible to support these therapies in most regions of the world much longer without testing. The utility of vonoprazan as an alternative to proton-pump inhibitor therapy, especially in resistant and difficult to treat groups, has also been considered in greater detail this year, as well as means of supporting and enhancing adherence to therapy. Several studies showed that the diversity of gut microbiota was significantly altered shortly after H pylori eradication. However, the diversity was restored to pre-treatment state after 2 months in patients treated with triple therapy. More studies are warranted to assess the long-term changes of gut microbiota after H pylori eradication.
PMID: 31486235 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード